/stocks — the workspaceLOADING
All LIMNSEC filings, by type → · Earnings date & implied move · Search inside filings
Liminatus Pharma, Inc. (LIMN) is a biological products, (no diagnostic substances) company. 2 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind LIMN’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from LIMN’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
A plain-English read on LIMN plus an auto-SWOT — built from LIMN's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate LIMN using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Has LIMN been issuing shares? Offering history →
Projected from LIMN's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentLIMN files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No tracked institution reported a position in LIMN in the latest 13F round.
No lawmaker has disclosed a trade in LIMN under the STOCK Act.
No open-market Form 4 buys or sells reported for LIMN in the last ~6 months.